TreatSMA

SMA Awareness Month – SpecialEffect Assistive Gaming Technology webinar

In this webinar we were joined by the charity SpecialEffect who specialise in providing assistive technology to those who are unable to use standard gaming controllers and so forth to help get them back into the world of computer gaming.

One of my favourite webinars of the month, an amazing charity with an amazing ethos. Computer gaming is a massive industry and one that many disabled people are unable to take advantage of due to their physical limitations. SpecialEffect is a charity that works alongside people with disabilities to provide assistive technology to enable them to enjoy the world of computer gaming. If you’d like to learn more about this amazing charity then please visit their website by clicking here.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more